| Literature DB >> 28960588 |
Yuji Otsuki1, Hideyuki Saya1, Yoshimi Arima1.
Abstract
Lung cancer is the most common cancer worldwide. Treatment options for lung cancer include surgery, radiation therapy, chemotherapy, molecularly targeted therapy including epidermal growth factor receptor or anaplastic lymphoma kinase inhibitors, and immunotherapy. These treatments can be administered alone or in combination. Despite therapeutic advances, however, lung cancer remains the leading cause of cancer death. Recent studies have indicated that epithelial-mesenchymal transition (EMT) is associated with malignancy in various types of cancer, and activation of EMT signaling in cancer cells is widely considered to contribute to metastasis, recurrence, or therapeutic resistance. In this review, we provide an overview of the role of EMT in the progression of lung cancer. We also discuss the prospects for new therapeutic strategies that target EMT signaling in lung cancer. Developmental Dynamics 247:462-472, 2018.Entities:
Keywords: ZEB1; drug resistance; epithelial-mesenchymal transition; lung disease
Mesh:
Year: 2017 PMID: 28960588 DOI: 10.1002/dvdy.24596
Source DB: PubMed Journal: Dev Dyn ISSN: 1058-8388 Impact factor: 3.780